Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S. saying they ...
Oral Wegovy becomes the first GLP-1 pill indicated for obesity, distinct from Rybelsus, which remains positioned for type 2 diabetes treatment. Daily administration improves acceptability for ...
Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with ...
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds ...
More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in ...
Children living with obesity but showing no signs of metabolic complications still have a significantly increased risk of ...
Children living with obesity but showing no signs of metabolic complications still have a significantly increased risk of ...
Setmelanotide receives FDA approval for acquired hypothalamic obesity based on phase 3 trial data demonstrating meaningful body mass index reductions.
Evaluation of a rural pediatric obesity program highlights strengths in structured care delivery while identifying gaps in ...
Spread the loveThe landscape of obesity treatment is evolving rapidly, with the recent approval of a higher-dose formulation of Wegovy by the U.S. Food and Drug Administration (FDA). This significant ...
March 23 () - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results